2014
English
Deutsch
Español
Português
To mark its 10 year anniversary, DNDi issued a report that explores the lessons learned from a decade of research and development of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model.
This report provides elements to stimulate current discussions on the way forward for sustainable mechanisms to provide health tools for developing countries.
Costs
DNDi’s cost of development ranges from EUR 6-20 million for an improved treatment, and EUR 30-40 million for a new chemical entity. However, the usual attrition in the field of R&D for infectious diseases, and the inherent risk of failure, should be taken into account, bringing the cost range of an improved treatment to EUR 10-40 million, and EUR 100-150 million for a new chemical entity.
